Abstract 12044: Absence of Coronary Artery Disease by Coronary Computed Tomographic Angiography and the Warranty Period Associated With All-Cause Mortality: Findings From the CONFIRM Long-Term Follow-Up Registry
Introduction: Coronary computed tomographic angiography (CCTA) is widely utilized for the detection of coronary artery disease (CAD). Foremost, the very low risk associated with normal CCTA is an important component for the purpose of cardiovascular risk stratification. To date, however, data that accounts for long-term prognosis of normal CCTA is sparse.
Purpose: Using data from a multi-center, global observational CCTA registry, we sought to determine the potential warranty period of normal CCTA.
Methods: Among 12,086 patients who underwent CCTA, 7,651 patients without history of previous CAD, aged between 30-74 years, were included in the current analysis and followed consecutively over 5 years. Normal CCTA was defined as the absence of any plaque in the coronary arteries. Annual mortality was calculated and compared with overall patients. The primary event in this study was all-cause mortality (ACM).
Results: During a median follow-up of 5.8 years (IQR, 5.3-6.3 years), 120 of all-cause deaths occurred among 3,051 patients with normal CAD. Mean age of the study population was 52±11 years, and 45% were men. Annual mortality rate was 0.68% (95% confidence interval (CI), 0.57~0.82), while annual mortality of overall patients was 1.31% (95% CI, 1.20~1.42) (p <0.001). When we defined warranty period as a follow-up duration until the estimated mortality reached the threshold of 5% using a Kaplan Meier curve, the warranty period of normal CCTA for ACM was 7.2 years. In subgroup analysis, according to a baseline risk factor profile using Framingham risk scores (FRS), annual mortality rate was 1.31% (95% CI, 0.85~2.03) among patients with high FRS and 0.62% (95% CI, 0.51~0.76) among those with low to intermediate FRS.
Conclusion: Absence of CAD by CCTA demonstrates a favorable survival rate with a minimum warranty period of at least 7 years. Persons presenting with a high cardiovascular risk profile displayed a relatively higher mortality, which is similar to overall population. Therefore, they should be considered a distinct group of individuals at-risk by physicians and researchers alike.
Author Disclosures: I. Cho: None. B. ó Hartaigh: None. H. Gransar: None. J. Schulman-Marcus: None. V. Valenti: None. D.S. Berman: None. M.J. Budoff: None. S. Achenbach: None. M. Al-Mallah: None. D. Andreini: Speakers Bureau; Modest; GE Healthcare. Consultant/Advisory Board; Modest; GE Healthcare. F. Cademartiri: Consultant/Advisory Board; Modest; Guerbet, Bracco, Siemens. T.Q. Callister: None. H. Chang: None. K. Chinnaiyan: None. R. Cury: None. A. Delago: None. M. Gomez: None. M. Hadamitzky: None. J. Hausleiter: None. N. Hindoyan: None. G. Feuchtner: None. Y. Kim: None. P.A. Kaufmann: None. J. Leipsic: None. F.Y. Lin: None. E. Maffei: None. G. Pontone: Speakers Bureau; Modest; GE Healthcare, Medtronic, Bayer, Heartflow. Consultant/Advisory Board; Modest; GE Healthcare, Heartflow. G. Raff: None. L.J. Shaw: None. T.C. Villines: None. A. Dunning: None. J.K. Min: Research Grant; Modest; GE Healthcare, Philips Healthcare, Vital Imaging. Speakers Bureau; Modest; GE Healthcare. Consultant/Advisory Board; Modest; GE Healthcare, Arineta, Astra Zeneca, Bristol Meyers Squibb.
- © 2014 by American Heart Association, Inc.